SMS Pharmaceuticals Limited — Others, 30-05-2025: Change in Auditors

SMS Pharmaceuticals Limited has announced a board meeting outcome approving the financial results for the quarter and half-year. Consolidated revenue rose to ₹782.75 Cr from ₹709.26 Cr last year, with net profit after tax increasing to ₹69.14 Cr from ₹49.83 Cr. EPS improved to ₹8.16 from ₹5.89. The Board approved a final dividend of ₹0.40 per share, investments up to ₹10 Cr in its subsidiary SMS Peptides Pvt. Ltd., and the setup of a new wholly owned subsidiary to expand into new therapeutic areas. Audit committees were reconstituted and key auditors appointed or re-appointed. The company converted 40 lakh warrants into equity, raising paid-up share capital to ₹8.86 Cr. Fund use from preferential allotment matched planned objectives, with all audits clean.